nvic academy

The purpose of a new empirical antimicrobial therapy is to deliver adequate treatment early while limiting antibiotic selection pressure and antibiotic resistance. The choice of molecules will be guided by the guidelines and the knowledge of previous multiresistant bacteria (MRB) carriers, secondarily adapted according to microbiological data. Finally, early optimal pharmacokinetics/pharmacodynamics (PK/PD) of empirical therapy is a necessary and safe starting point from where de-escalation can take place. The antimicrobial chosen for de-escalation should be used according to antibiotic susceptibility testing, and using proper doses to ensure appropriate PK during targeted therapy.